Jiangsu Hengrui Pharmaceuticals (SHA:600276, HKG:1276) received approval from China's National Medical Products Administration for the clinical trial of SHR-8203 injection, according to a Shanghai bourse filing on Friday.
The drug will be tested as a monotherapy for advanced solid tumors.
The Chinese pharmaceutical company's Shanghai shares dropped 3% during the morning trade.